06.11.26 -- Why Contracts Need To Catch Up To AI Appears In Clinical Trials

Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.

The next era of clinical trials will be defined by global expansion across the Asia-Pacific region, rapid and cost-effective pathways to regulatory approval, and reliable, patient-centric leadership.

Explore how strategic, integrated packaging can accelerate clinical-to-commercial success while enabling patient-centric, scalable, and globally resilient drug delivery.

Accelerate oncology programs with deep therapeutic expertise and global scale. Master the complexities of ADCs and cell therapies through agile execution and high-retention project teams.

Early-phase clinical research experts, specialized in first-in-human trials, clinical pharmacology/NDA-enabling studies, and proof-of-concept studies. 

Why is functional outsourcing important in today's clinical development environment, and where can you find scalable support that will flex with your changing needs?

New FDA guidance aligns IND safety reports with unanticipated problems, shifting the focus from administrative definitions to proactive participant protection and trial integrity.

Explore how pharma and biotech companies are using AI, outsourcing, and new technologies to strengthen materiovigilance for complex drug-device products.

QT strategy decisions affect timelines, cost, and regulatory outcomes. This presentation examines when early QT data can support a waiver, how guidance updates influence study design, and more.

A successful clinical trial starts with an efficient protocol review. Get your clinical trial to the start line while ensuring participant health and safety.

Modernize your study binder processes with Florence eBinders™, offering remote access for sponsor interactions, monitoring, and source data review.